FDA under pressure for BPA safety
This article was originally published in The Tan Sheet
Executive SummaryFollowing a Sept. 17 study in the Journal of American Medical Association that finds higher concentrations of Bisphenol A in human urine is associated with cardiovascular disease, diabetes and liver-enzyme abnormalities, Reps. Rosa DeLauro, D-Conn., and John Dingell, D-Mich., criticize FDA's determination that BPA in food lining containers is safe. DeLauro says in a Sept. 16 release that FDA's stance on BPA's safety is "perplexing and dangerous." Likewise, Dingell urged the agency to "take careful notice of this new research during its Science Board meeting on Bisphenol A" Sept. 16, according to a same-day release. The most recent JAMA study does not conclusively link BPA in food containers as a cause of the associated diseases
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.